GILEAD SCIENCES, INC. Foreign Currency Transaction Gain (Loss), before Tax
GILEAD SCIENCES, INC. (GILD) reported Foreign Currency Transaction Gain (Loss), before Tax of -$4.00 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2015-02-25
- GILEAD SCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2014 was -$4.00M.
- GILEAD SCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2013 was -$4.00M.
- GILEAD SCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2012 was -$11.00M.
- GILEAD SCIENCES, INC. foreign currency transaction gain (loss), before tax for fiscal 2011 was -$21.30M, a 675.68% decline from fiscal 2010.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|
| 2014-12-31 | -$4.00M 10-K · filed 2015-02-25 | |
| 2013-12-31 | -$4.00M 10-K · filed 2015-02-25 | -$3.60M 10-K · filed 2014-02-25 |
| 2012-12-31 | -$11.00M 10-K · filed 2015-02-25 | $10.70M 10-K · filed 2013-02-27 |
| 2011-12-31 | -$21.30M 10-K · filed 2014-02-25 | $21.30M 10-K · filed 2012-02-23 |
| 2010-12-31 | $3.70M 10-K · filed 2013-02-27 | |
| 2009-12-31 | $16.40M 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |